YOLFTbeta
Bioray Biotech Co., Ltd

Bioray Biotech Co., Ltd

7561 · TWO · Healthcare / Drug Manufacturers - Specialty & Generic

16.70TWD+0.40 (+2.45%)

Price History

Full chart

Market Stats

Previous Close16.30
Open16.70
Day Range16.70 – 16.70
52-Week Range15.41 – 24.75
Volume1.00K
Market Cap597.62M
P/E (TTM)31.08
Forward P/E0.00
EPS0.65
Dividend Yield4.70%
Beta0.08
50-Day Avg19.05
200-Day Avg20.75

About

Bioray Biotech Co., Ltd engages in the research, development, production, and sells health foods, immune cell products, and precision testing services in Taiwan. It provides testing services for oncology and immune profile, gut microbiome, and health insights; CIK Immune Cell Therapy; and supplements and micro-pellets, as well as ODM/OEM services. Bioray Biotech Co., Ltd was founded in 2005 and is based in Tainan City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODr. Ting-Yuan Hsu
  • HeadquartersNo. 1, Dali 2nd Road, Tainan City, Taiwan, 741014, Taiwan
  • Websitehttps://www.bio-ray.com.tw

Leadership

  • Dr. Ting-Yuan HsuFounder & Chairman

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue181.93M156.29M148.02M190.60M191.83M201.71M222.72M
Growth (%)--14.09%-5.30%+28.77%+0.65%+5.15%+10.42%
Cost of Revenue100.66M88.44M80.73M110.09M114.18M122.69M116.79M
Gross Profit81.28M67.86M67.29M80.51M77.65M79.03M105.94M
Gross Margin44.67%43.42%45.46%42.24%40.48%39.18%47.56%
Operating Expense74.43M68.08M75.40M80.75M96.98M83.34M68.15M
Operating Income6.85M-222.00K-8.11M-235.00K-19.33M-4.32M37.79M
Operating Margin3.76%-0.14%-5.48%-0.12%-10.08%-2.14%16.97%
EBITDA15.25M14.99M13.86M24.27M12.13M27.69M65.48M
EBITDA Margin8.38%9.59%9.37%12.74%6.33%13.73%29.40%
Net Income19.49M-58.00K-7.19M500.00K-11.56M1.00M32.25M
Net Income Margin10.71%-0.04%-4.86%0.26%-6.03%0.50%14.48%
R&D12.09M14.41M21.86M32.26M44.27M35.25M24.86M
R&D as % of Total Revenue6.64%9.22%14.77%16.93%23.08%17.48%11.16%
Interest Expense1.12M1.17M953.00K1.36M1.32M1.33M646.00K
Interest Expense % of Total Revenue0.62%0.75%0.64%0.72%0.69%0.66%0.29%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets499.74M475.80M466.18M598.63M542.65M543.63M536.58M
Total Liabilities55.00K104.05M102.25M147.16M108.75M122.90M83.57M
Total Equity377.85M369.37M363.92M451.47M433.90M420.73M453.01M
Cash212.96M145.91M126.31M139.06M97.02M178.21M204.92M
Total Debt57.94M61.59M53.47M100.92M69.79M85.78M-
Net Debt-155.02M-84.32M-72.84M-38.15M-27.23M-92.43M-

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow62.31M1.67M8.83M2.48M-762.00K16.65M71.64M
Investing Cash Flow-91.27M-52.90M-19.79M-59.63M-12.55M53.72M-
Financing Cash Flow565.00K-15.32M-8.64M69.92M-28.73M10.82M-
Capital Expenditure62.76M51.37M15.54M60.38M10.18M3.30M414.00K
Free Cash Flow-448.00K-49.70M-6.71M-57.90M-10.95M13.35M71.22M
Dividends Paid9.75M8.02M--6.02M--
FCF to OCF-0.72%-2968.82%-75.98%-2336.72%1436.35%80.17%99.42%
Dividend Paid to FCF-2176.79%-16.14%---54.97%--

Key Statistics & Ratios

Market Cap597.62M
Enterprise Value483.06M
Trailing P/E31.08
Forward P/E0.00
Price / Sales2.88
Price / Book1.44
EPS0.65
Book Value14.57
Revenue (TTM)207.16M
Gross Profit (TTM)84.85M
EBITDA34.03M
Profit Margin9.26%
Operating Margin5.87%
Return on Equity4.40%
Return on Assets2.32%
Shares Outstanding29.59M
Shares Float13.59M
Beta0.08
Dividend Yield4.70%
Dividend Rate0.95
Payout Ratio0.00%

Dividends

20261×
0.95Aug 25, 2026
20231×
0.20Aug 28, 2023
20201×
0.29Jul 30, 2020